References
- Meyer zu Horste, G., Hartung, H.P., Kieseier, B.C. From bench to bedside – experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol 2007, 3, 198–211.
- Misawa, S., Kuwabara, S., Mori, M., Kawaguchi, N., Yoshiyama, Y., Hattori, T. Serum levels of tumor necrosis factor-α in chronic inflammatory demyelinating polyneuropathy. Neurology 2001, 56, 666–669.
- Bosch, X., Saiz, A., Ramos-Casals, M.; BIOGEAS Study Group. Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol 2011, 7, 165–172.
- Kanda, J., Lopez, R.D., Rizzieri, D.A. Alemtuzumab for the prevention and treatment of graft-versus-host disease. Int J Hematol 2011, 93, 586–593.
- Zent, C.S., Secreto, C.R., LaPlant, B.R., Bone, N.D., Call, T.G., Shanafelt, T.D., Jelinek, D.F., Tschumper, R.C., Kay, N.E. Direct and complement-dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res 2008, 32, 1849–1856.
- Jones, J.L., Phuah, C.L., Cox, A.L., Thompson, S.A., Ban, M., Shawcross, J., Walton, A., Sawcer, S.J., Compston, A., Coles, A.J. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009, 119, 2052–2061.
- Abbi, K.K., Rizvi, S.M., Sivik, J., Thyagarajan, S., Loughran, T., Drabick, J.J. Guillain-Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: a case report and review of the literature. Leuk Res 2010, 34, e154–e156.
- Avivi, I., Chakrabarti, S., Kottaridis, P., Kyriaku, C., Dogan, A., Milligan, D.W., Linch, D., Goldstone, A.H., Mackinnon, S. Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation. Bone Marrow Transplant 2004, 34, 137–142.
- Castelli, R., Moreo, G., Panfili, B., Cogiamanian, F., Reda, G., Cortelezzi, A., Bresolin, N., Conti, G. Guillain-Barrè syndrome in a chronic lymphocytic leukaemia patient after subcutaneous alemtuzumab and high dose of prednisone therapy. J Peripher Nerv Syst 2009, 14, 1–28.
- Flachenecker, P., Stuke, K. National MS registries. J Neurol 2008, 255 Suppl 6, 102–108.
- Vedeler, C.A., Myhr, K.M., Nyland, H. Fc receptors for immunoglobulin G–a role in the pathogenesis of Guillain-Barré syndrome and multiple sclerosis. J Neuroimmunol 2001, 118, 187–193.
- Sharief, M.K., Ingram, D.A., Swash, M., Thompson, E.J. I.v. immunoglobulin reduces circulating pro-inflammatory cytokines in Guillain-Barré syndrome. Neurology 1999, 52, 1833–1838.
- Nimmerjahn, F., Ravetch, J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008, 26, 513–533.
- Zandman-Goddard, G., Blank, M., Shoenfeld, Y. Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside. Lupus 2009, 18, 884–888.